NEWTOWN SQUARE, Pa., April 3 /PRNewswire/ -- After more than a decade of research and development, Kibow Biotech, Inc. announced today the launch of Kibow Biotics(R), the Company's new patented and proprietary probiotic formulation targeting kidney health. This product will be sold exclusively through their online store. Maintaining healthy kidney function is a concern for over 200 million people worldwide. Despite this need, complementary and alternative solutions have not been readily available, until now! Based on a patented platform technology, Kibow Biotics uses the bowel to augment kidney function.
Kibow Biotics will be made available initially in the U.S. (http://www.kibow.com) and in Canada (http://www.gelda.com). The product is a dietary supplement and not a drug; it is not intended to be used as a drug or as a substitute for any drug application. The Company encourages referrals from healthcare professionals, even though Kibow Biotics is a non-prescription product.
Dr. Natarajan Ranganathan, Interim CEO and Senior VP (R&D), stated, "As per U.S. FDA and FTC regulations, we cannot refer directly or indirectly to our product formulation with words like 'disease,' 'drug,' 'therapy,' 'prevent,' 'cure,' 'delay,' 'eliminate,' 'remove' or 'mitigate' any symptoms or illnesses. However, in spite of the stipulations we encounter in communicating their benefits, probiotics are increasingly well-accepted. In fact, there are hundreds of dietary supplements available over the counter (OTC) in health food stores and through various other distribution channels in the USA, in Canada and in several other countries. We are delighted that Kibow Biotics will represent new hope and significant savings for maintaining kidney he
|SOURCE Kibow Biotech, Inc.|
Copyright©2009 PR Newswire.
All rights reserved